---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000603"
form_type: "8-K"
ticker: "CYDY"
cik: "0001175680"
company_name: "CytoDyn Inc."
filed_at: "2024-01-29T23:59:59+00:00"
generated_at: "2026-06-06T15:45:48.255507+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CytoDyn appoints Jacob Lalezari as permanent CEO, names Mitchell Cohen interim CFO

## Summary
- Jacob Lalezari appointed CEO effective Jan 26, 2024; previously interim CEO since Nov 2023.
- Base salary $400K, target annual bonus 40%, option grant of 3M shares vesting over 4 years.
- Antonio Migliarese resigns as CFO effective Jan 31, 2024; last day Feb 15.
- Mitchell Cohen appointed interim CFO effective Feb 1, 2024; independent contractor via Rapid Deployment.

## SEC filing metadata
- accession: 0001558370-24-000603
- form_type: 8-K
- ticker: CYDY
- cik: 0001175680
- company_name: CytoDyn Inc.
- filed_at: 2024-01-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175680/000155837024000603/0001558370-24-000603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175680/000155837024000603/cydy-20240123x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000603
- JSON: https://secwatch.observer/filing/0001558370-24-000603.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000603.txt

## Key facts
- Executive change
  Jacob P. Lalezari was appointed as Chief Executive Officer at CytoDyn Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On January 26, 2024, CytoDyn Inc., a Delaware corporation (the “Company”), entered into an employment agreement with Jacob P. Lalezari, M.D. (the “Employment Agreement”), under which he will be employed as the Company’s Chief Executive Officer and will serve as its principal executive officer, effective as of January 26, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837024000603/0001558370-24-000603-index.htm
- Executive change
  Mitchell Cohen was appointed as Interim CFO at CytoDyn Inc..
  - Action: appointed
  - Role: Interim CFO
  source text: On January 10, 2024, the Company entered into an agreement with Rapid Deployment LLC d/b/a InterimExecs (“InterimExecs”), under which Mitchell Cohen will serve as the Company’s Interim CFO, effective February 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837024000603/0001558370-24-000603-index.htm
- Executive change
  Antonio Migliarese resigned as CFO at CytoDyn Inc..
  - Action: resigned
  - Role: CFO
  source text: On January 23, 2024, Antonio Migliarese informed the Company that he would be resigning from his position as CFO, effective January 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837024000603/0001558370-24-000603-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.